---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-033823"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:33:57.695486+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals sells rights to generic Sabril (vigabatrin) ANDA to Pyros

## Summary
- Sale of rights to approved ANDA for generic Sabril (Vigabatrin Powder for Oral Solution, 500 mg) to Pyros Pharmaceuticals.
- Elite executed a three-year manufacturing and supply agreement with Pyros for the product.
- Elite will be compensated at an agreed-upon price for manufacturing and packaging.
- Agreement executed November 21, 2022; sale has been consummated.

## SEC filing metadata
- accession: 0001493152-22-033823
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-033823
- JSON: https://secwatch.observer/filing/0001493152-22-033823.json
- Plain text: https://secwatch.observer/filing/0001493152-22-033823.txt

## Key facts
- Material Agreements
  ELITE PHARMACEUTICALS INC /NV/ entered into Manufacturing and Supply Agreement with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).
  - Action: entry
  - Agreement: supply
  - Counterparty: Pyros Pharmaceuticals, Inc.
  - Effective: 2022-11-21
  source text: collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm
- Material Agreements
  ELITE PHARMACEUTICALS INC /NV/ entered into a asset purchase with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Pyros Pharmaceuticals, Inc.
  - Effective: 2022-11-21
  source text: On November 21, 2022, Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. (a wholly owned subsidiary of Elite Pharmaceuticals, Inc.) (collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic Sabril® (Vigabatrin Powder for Oral Solution, 500 mg) (“Product”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.